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Michael Verneris, John E. WagnerRegardless of the hematopoietic stem cell (HSC)
source, reconstitution of adaptive immunity is arguably
the last great barrier to successful allogeneic hemato-
poietic cell transplantation. Early after transplantation,
prolonged lymphocytopenia, and profound immune
dysfunction result in infectious complications that are
frequent and often life threatening [1]. In addition, de-
layed immune recovery may also increase the risk of
relapse in patients treated for malignant disease [2,3].
The number of variables in the transplant recipient,
such as patient age, graft source, HLA match,
intensity of conditioning, and immune suppressive
regimens make it difficult to identify the specific
impact of a single variable. In addition, the absence of
validated functional immune reconstitution assays
hinders progress in the field.
In this issue of BBMT, Jacobson and colleagues [4]
tackle the clinical question of whether immune recon-
stitution in adult recipients of HLA mismatched um-
bilical cord blood (UCB) differs from that in adult
recipients of HLAmatched unrelated peripheral blood
(PB) transplantation. The data presented suggest that
there may indeed be a significant delay in immune
recovery after UCB transplantation. During the first
6-month period following transplantation, the
absolute number of T cells and naive CD41 and
CD41CD251T regulatory cell subsets were markedly
reduced, whereas the number of B and natural killer
cells was significantly higher in recipients of UCB
compared to recipients of PB. Importantly, these dif-
ferences were associated with higher rates of infectious
complications in the UCB group (59% versus 8%, P\
.0001), with increases in bacterial, viral, and fungal
pathogens during the same period. Despite these dif-
ferences, risks of nonrelapse mortality and 2-year
progression-free survival were similar between the 2
groups. As expected, based on prior reports, the inci-Blood and Marrow Transplant Program, University of
esota, Minneapolis, Minnesota.
dence and reprint requests: John E. Wagner, MD, Blood
arrow Transplant Program, University of Minnesota,
eapolis, MN 55455 (e-mail: wagne002@umn.edu).
ebruary 6, 2012; accepted February 8, 2012
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2012.02.003dence of chronic graft-versus-host disease was higher
after PB transplantation.
But, is UCB truly inferior to PB in terms of
immune recovery? It is certainly possible. Clearly,
there are known differences in neonatal and adult
blood with respect to numbers of naive and antigen
experienced T cells. There are also functional differ-
ences between UCB and PB T cells, with the UCB
showing a reduced propensity to elaborate cytokines
in vitro [5]. As well, it should be taken into account
that there are also differences in the immune profile
and function of PB before and after granulocyte-
colony stimulating factor mobilization, including
more Th2 skewing [6] and reduced natural killer cyto-
toxicity [7]. In addition to differences in the lympho-
cyte compartment, recent data suggest that the stem
cells themselves differ between adult and UCB, with
UCB HSCs giving rise to T cells that are more
tolerogenic [8]. Thus, it is plausible to consider that
graft-intrinsic properties may account for the above
findings by Jacobson et al.
The study by Jacobsen et al., however, only tells us
that the ‘‘treatment package’’ is associated with
a slower pace of immune recovery, as measured by
cell surface markers and supported by infectious dis-
ease complications. In particular, UCB recipients
were conditioned with melphalan, fludarabine, and an-
tithymocyte globulin (ATG) and PB recipients with
busulfan and fludarabine without ATG. Similarly,
graft-versus-host disease immunoprophylaxis also dif-
fered with most UCB recipients treated with sirolimus
and tacrolimus and PB recipients, sirolimus, tacroli-
mus, and methotrexate. As recognized by the authors,
these variables must be taken into consideration. So,
we are left unable to answer the question—is delayed
immune reconstitution after UCB transplant because
of some intrinsic factor unique to UCB? Maybe, but
maybe not. The current literature is mixed. In a recent
study by Renard et al. [9] rapid T cell reconstitution
was observed in children transplanted with UCB the
absence of ATG.
As conditioning regimens and graft-versus-host
disease prophylaxis strategies evolve, the impact on
both short- and long-term immune recovery should
be assessed, optimally, by modifying one variable at
a time. Furthermore, what is the best way to assess im-
mune reconstitution? The fact that T cells are present
after transplantation is important, does not necessarily493
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such as with tetramer staining, intracellular cytokine
staining, and degranulation assays, are becoming
more readily available and allow us to functionally
interrogate lymphocyte subpopulations. These assess-
ments, if validated as predictors of infection and
relapse, will not only help elucidate the impact of
various graft-intrinsic and extrinsic factors on the
kinetics of immune recovery, but may also help us
identify those patients at highest risk for these compli-
cations.
The article by Jacobson et al. [4] challenges us
further to identify what factor or factors may be re-
sponsible for the apparent delay in adaptive immunity
observed in their patients undergoing UCB trans-
plantation. The tools now exist to better assess im-
mune function and perhaps overcome this brick
wall, previously limiting our ability to understand
the myriad of factors negatively influencing immune
reconstitution. What are ‘‘brick walls’’ anyway? As
we are told by Randy Pausch in The Last Lecture,
‘‘Brick walls . are there to give us a chance to
show how badly we want something . brick walls
are there to stop the other people!’’ [Not us!] It’s
time to remove this wall and finally figure out how to
enhance the pace of immune reconstitution . and
win the race.’’From the Fred Hutchinson Cancer Research Center, Seattle,
Washington.
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Effie W. PetersdorfThe MHC is home to a series of genes that have
highly coordinated functions in the immune response.
Genes involved in antigen presentation (HLA-A, C, B,
DR, DQ, and DP) reside near genes involved in anti-
gen processing (TAP), the innate response (MICA,
MICB), stress and inflammation (TNF, LTA, LST),
and regulatory receptors (NOTCH4). Although the
class I, III, and II regions are each distinguished by
their unique genetic landscape, variation across the
MHC is highly organized into haplotypes that linkgenes from the extended class I through to the ex-
tended class II region.
Much like a patchwork quilt where individual
blocks can be configured in different ways to create
unique patterns, the MHC has segments or blocks of
highly conserved sequences that are characteristic of
haplotypes. A key to understanding the MHC is the
nature of its ‘‘blockiness’’ and haplotypic associations.
The study by Bettens et al. [1] examined 2 genes that
reside in distinct regions of the MHC and their role
in transplantation outcome: the TNF segment in the
class III region, and HLA-DP in class II.
At the centromeric end of the HLA region resides
HLA-DP, a highly polymorphic locus (over 152
unique alleles recognized as of January 2012; http://
www.ebi.ac.uk/imgt/hla/) that is firmly established as
a classical transplantation locus [2,3]. Although
donor matching is associated with a lower risk of
graft-versus-host disease (GVHD), practically, pro-
spective donor matching is difficult because of the
weaker linkage disequilibrium that leads to mismatch
